{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:46:40Z","timestamp":1790394400230,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40272-020-00433-z","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T02:26:08Z","timestamp":1610677568000},"page":"111-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Ranibizumab: A Review in Retinopathy of Prematurity"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"433_CR1","unstructured":"American Academy of Ophthalmology. Retinopathy of prematurity-Europe. 2013. https:\/\/www.aao.org\/. Accessed 23 Nov 2020."},{"issue":"5","key":"433_CR2","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1542\/peds.2004-1180","volume":"115","author":"C Gilbert","year":"2005","unstructured":"Gilbert C. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115(5):e518\u201325.","journal-title":"Pediatrics"},{"issue":"1","key":"433_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","volume":"122","author":"ME Hartnett","year":"2015","unstructured":"Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015;122(1):200\u201310.","journal-title":"Ophthalmology"},{"issue":"7","key":"433_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med."},{"key":"433_CR5","unstructured":"European Medicines Agency. Lucentis (ranibizumab) EPAR assessment report variation [procedure no. EMEA\/H\/C\/000715\/II\/0074\/G]. 2020. https:\/\/www.ema.europa.eu\/. Accessed 23 Nov 2020."},{"issue":"2","key":"433_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10103-011-1021-z","volume":"28","author":"SK Houston","year":"2011","unstructured":"Houston SK, Wykoff CC, Berrocal AM, et al. Laser treatment for retinopathy of prematurity. Laser Med Sci. 2011;28(2):683\u201392.","journal-title":"Laser Med Sci."},{"key":"433_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-017-0645-6","volume":"18","author":"Z Li","year":"2018","unstructured":"Li Z, Zhang Y, Liao Y, et al. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol. 2018;18:1.","journal-title":"BMC Ophthalmol."},{"issue":"8","key":"433_CR8","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2165\/00003495-200767080-00007","volume":"67","author":"SKA Blick","year":"2007","unstructured":"Blick SKA, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2007;67(8):1199\u2013206.","journal-title":"Drugs."},{"issue":"4","key":"433_CR9","first-page":"455","volume":"71","author":"KP Garnock-Jones","year":"2011","unstructured":"Garnock-Jones KP. Ranibizumab in macular oedema following retinal vein occlusion. Drugs. 2011;71(4):455\u201363.","journal-title":"Drugs."},{"issue":"4","key":"433_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/11208410-000000000-00000","volume":"72","author":"JE Frampton","year":"2012","unstructured":"Frampton JE. Ranibizumab in diabetic macular oedema. Drugs. 2012;72(4):509\u201323.","journal-title":"Drugs."},{"issue":"5","key":"433_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40266-013-0077-9","volume":"30","author":"JE Frampton","year":"2013","unstructured":"Frampton JE. Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging. 2013;30(5):331\u201358.","journal-title":"Drugs Aging"},{"key":"433_CR12","unstructured":"European Medicines Agency. Lucentis (ranibizumab): summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/. Accessed 23 Nov 2020."},{"issue":"10208","key":"433_CR13","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551\u20139.","journal-title":"Lancet"},{"issue":"3","key":"433_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatrics. 2018;172(3):278\u201386.","journal-title":"JAMA Pediatrics."},{"issue":"4","key":"433_CR15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37(4):694\u2013701.","journal-title":"Retina."},{"issue":"6","key":"433_CR16","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"S Fogli","year":"2018","unstructured":"Fogli S, Del Re M, Rofi E, et al. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye. 2018;32(6):1010\u201320.","journal-title":"Eye."},{"key":"433_CR17","unstructured":"Novartis. Lucentis (ranibizumab) intravitreal injection 10 mg\/mL; Japanese prescribing information [Japanese]. 2020. https:\/\/www.pmda.go.jp. Accessed 29 Oct 2020."},{"key":"433_CR18","doi-asserted-by":"crossref","unstructured":"Deutsche Ophthalmologische Gesellschaft e.V. (DOG), Gesellschaft e.V. (RG), Berufsverband der Augen\u00e4rzte Deutschlands e.V. (BVA). Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augen\u00e4rzte Deutschlands zur anti-VEGF-therapie der fr\u00fchgeborenenretinopathie [German]. Der Ophthalmologe. 2020;117(9):873\u201385.","DOI":"10.1007\/s00347-020-01170-x"},{"issue":"8","key":"433_CR19","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/archopht.119.8.1120","volume":"119","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"2001","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Effect of retinal ablative therapy for threshold retinopathy of prematurity. Arch Ophthalmol. 2001;119(8):1120\u20135.","journal-title":"Arch Ophthalmol."},{"issue":"1","key":"433_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/NPM-17158","volume":"12","author":"K Beck","year":"2019","unstructured":"Beck K, Young R, Read S, et al. The severity and associated comorbidities of retinopathy of prematurity among micro-premature infants with birth weights less than 750 grams. J Neonatal Perinatal Med. 2019;12(1):41\u20135.","journal-title":"J Neonatal Perinatal Med."},{"issue":"8","key":"433_CR21","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","volume":"124","author":"Q Huang","year":"2017","unstructured":"Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology. 2017;124(8):1156\u201364.","journal-title":"Ophthalmology"},{"key":"433_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12886-018-0815-1","volume":"18","author":"Q Tong","year":"2018","unstructured":"Tong Q, Yin H, Zhao M, et al. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab. BMC Ophthalmol. 2018;18:150.","journal-title":"BMC Ophthalmol."},{"issue":"10","key":"433_CR23","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.ophtha.2018.04.018","volume":"125","author":"MF Chiang","year":"2018","unstructured":"Chiang MF. How does the standard of care evolve? Anti\u2013vascular endothelial growth factor agents in retinopathy of prematurity treatment as an example. Ophthalmology. 2018;125(10):1485\u20137.","journal-title":"Ophthalmology"},{"issue":"4","key":"433_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/org.4.4.7415","volume":"4","author":"JJ Haigh","year":"2014","unstructured":"Haigh JJ. Role of VEGF in organogenesis. Organogenesis. 2014;4(4):247\u201356.","journal-title":"Organogenesis."},{"key":"433_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1167\/tvst.9.8.43","volume":"9","author":"M Fidler","year":"2020","unstructured":"Fidler M, Fleck BW, Stahl A, et al. Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial. Transl Vis Sci Technol. 2020;9:8.","journal-title":"Transl Vis Sci Technol."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00433-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-020-00433-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00433-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T03:12:16Z","timestamp":1611198736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-020-00433-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1007\/s40272-020-00433-z","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"23 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arnold Lee and Matt Shirley are salaried employees of Adis International Ltd\/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}